How often is cancer detected when serum PSA is elevated? What factors affect the prostate cancer detection rate?
The detection rate of prostate cancer is influenced by several factors: clinical features including the serum PSA level and an abnormal digital rectal examination (DRE); the number of biopsy cores examined; and the volume of the prostate. Among men with serum PSA < 4ng/ml, 4–10ng/ml, and >10ng/ml, cancer detection rates by prostate needle core biopsy (PNB) are approximately 15%, 25%, and 60%, respectively. Men with low screening PSA (<4 ng/ml) and treated with radical prostatectomy have smaller cancers, lower Gleason scores, lower pathologic tumor stages, and lower PSA recurrence rates than men with higher PSA levels (≥4 ng/ml). If the initial serum PSA values are >10ng/ml, cancers are pathologically in more advanced stages. Cancers detected with an abnormal DRE are more frequently in advanced stages than those discovered by PSA screening.
KeywordsProstate Cancer Cancer Detection Rate Radical Prostatectomy Specimen Sextant Biopsy Abnormal Digital Rectal Examination
Unable to display preview. Download preview PDF.
- 1.Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC (1994) Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer; results of a multicenter clinical trial of 6,630 men. J Urol 151:1283–1290.PubMedGoogle Scholar
- 4.Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350:2239–2246.PubMedCrossRefGoogle Scholar
- 5.Datta MW, Dhir R, Dobbin K, Bosland MC, Melamed J, Becich MJ, Orenstein JM, Kajdacsy-Balla AA, Patel A, Macias V, Berman JJ (2005) Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource. J Urol 173:1546–1551.PubMedCrossRefGoogle Scholar
- 10.Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansandoro A, Martini M, Pansandoro V (2004) The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperitoneal prostate biopsy. J Urol 171:197–199.PubMedCrossRefGoogle Scholar
- 11.Presti JC Jr, O’Dowd GL, Miller MC, Masttu R, Veltri RW (2003) Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 165:125–129.CrossRefGoogle Scholar
- 17.Lerner SP, Atkinson N (2000) Editorial comment. J Urol 164:392.Google Scholar
- 24.Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EP, Parson RE, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease: a prospective multicenter clinical trial. JAMA 279:1542–1547.PubMedCrossRefGoogle Scholar